THE REAL COST OF FREE DRUG SAMPLES: A PROPOSED POLICY SOLUTION

Dr. Gitanjali Mishra, Dr. Devashish Mishra

Abstract


The improvements related to policy and legislation can create more competition in the pharmaceutical market. The improved pharmaceutical market competition would generate incentives for innovative medicines while regulating the distribution of free drug samples that lack value and have the substitute or alternative less expensive generic products. The provision of free drug samples strongly influences the physician's behavior and decision- making as physicians are more likely to prescribe expensive name- brand drugs provided as a sample by the pharmaceutical company. Physicians' acceptance of drug samples not only undermines the use of prescribing less expensive generic alternatives, but it also contributes to the poor quality of patient care and increasing healthcare cost.

            The purpose of this paper is to propose a regulation regarding free drug samples that should be placed on the doctors and drug manufactures and they should be penalized if they provide loose samples of the prescription without proper side effects, drug interactions, doses, available generic drugs, storage instructions, and bookkeeping.


Keywords


Free samples, Prescription drugs, Generic drug, Policy and Regulation

Full Text:

PDF

References


Lahey, Tim. “The high costs of "free" drug samples.” Clinical and translational gastroenterology vol. 5,12 e67. 18 Dec. 2014, doi:10.1038/ctg.2014.16

Brown, Joshua D et al. “Utilization of free medication samples in the United States in a nationally representative sample: 2009-2013.” Research in social & administrative pharmacy: RSAP vol. 13,1 (2016): 193-200. doi:10.1016/j.sapharm.2016.01.006

Charatan, F. “Hospital bans free drug samples.” The Western journal of medicine vol. 174,4 (2001): 236-7.

Chimonas, Susan, and Jerome P Kassirer. “No more free drug samples?.” PLoS medicine vol. 6,5 (2009): e1000074. doi:10.1371/journal.pmed.1000074

Cutrona, Sarah L et al. “Free drug samples in the United States: characteristics of pediatric recipients and safety concerns.” Pediatrics vol. 122,4 (2008): 736-42. doi:10.1542/peds.2007-2928

Gellad, Walid F et al. “Use of prescription drug samples and patient assistance programs, and the role of doctor-patient communication.” Journal of general internal medicine vol. 26,12 (2011): 1458-64. doi:10.1007/s11606-011-1801-y

Hurley, Michael P et al. “Characterizing the relationship between free drug samples and prescription patterns for acne vulgaris and rosacea.” JAMA Dermatology vol. 150,5 (2014): 487-93. doi:10.1001/jamadermatol.2013.9715

Hampp, Christian et al. “Use of Prescription Drug Samples in the USA: A Descriptive Study with Considerations for Pharmacoepidemiology.” Drug safety vol. 39,3 (2016): 261-70. doi:10.1007/s40264-015-0382-9

Katz, Kenneth A et al. “Drug samples in dermatology: out of the closet, into the dustbin.” JAMA Dermatology vol. 150,5 (2014): 483-5. doi:10.1001/jamadermatol.2013.9711

Whittle, Jeff, and Chester B Good. “Prescription drug samples: making decisions with imperfect data.” Journal of general internal medicine vol. 23,6 (2008): 890-2. doi:10.1007/s11606-008-0642-9


Refbacks

  • There are currently no refbacks.